JPRN-UMIN000047677
Recruiting
未知
Exploratory study of genome alteration and rearrangement associated with ART (Assisted Reproductive Technology) using birth and three-generation cohort study (TMM BirThree Cohort Study). - Exploratory study of genome alteration and rearrangement associated with ART (Assisted Reproductive Technology) using birth and three-generation cohort study (TMM BirThree Cohort Study).
Tohoku Medical Megabank Organization0 sites6 target enrollmentMay 10, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Birth Children and their family that are classified with conception method, IVF, ICSI and natural conception.
- Sponsor
- Tohoku Medical Megabank Organization
- Enrollment
- 6
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Not applicable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Immune micro-environment and immune genomics of head and neck cancerHealth Condition 1: null- Patients with Gingivo buccal-Oral squamous cell carcinomaCTRI/2018/07/014757Department of Biotechnology Systems Medicine Cluster SyMeC Kolkata
Recruiting
Not Applicable
A biomarker study to analyze genomic variations in circulating-tumor DNA and circulating tumor cells in gastrointestinal cancers (Valor trial)Gastrointestinal cancerJPRN-UMIN000036681St. Marianna University School of Medicine Hospital70
Not yet recruiting
Not Applicable
The investigation of comprehensive genetic mutation in patients with ulcerative colitis.ulcerative colitisJPRN-UMIN000024589Chiba university50
Recruiting
Not Applicable
The study of gene and epigenetic modifications, bioelement and physical active substance on the patients with neurodegenerative diseases.eurodegenerative diseasesJPRN-UMIN000030101Gifu Pharmaceutical University100
Active, not recruiting
Not Applicable
A study to assess the incidence in the UK of a change in a protein found in patients with newly diagnosed non-small cell lung cancer which has advanced or spread, and to investigate the quality of life of these patients when they receive treatment with erlotinib (Tarceva®) alone as a first treatment for this stage of their disease.EUCTR2010-021120-96-GBRoche Products Limited1,200